Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Integra Lifesciences Holdings (IART) Accounts Payables (2016 - 2025)

Integra Lifesciences Holdings' Accounts Payables history spans 17 years, with the latest figure at $95.7 million for Q4 2025.

  • For Q4 2025, Accounts Payables rose 16.03% year-over-year to $95.7 million; the TTM value through Dec 2025 reached $95.7 million, up 16.03%, while the annual FY2025 figure was $95.7 million, 16.03% up from the prior year.
  • Accounts Payables for Q4 2025 was $95.7 million at Integra Lifesciences Holdings, up from $92.3 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $112.8 million in Q1 2023 and bottomed at $59.6 million in Q3 2021.
  • The 5-year median for Accounts Payables is $91.8 million (2025), against an average of $86.1 million.
  • The largest annual shift saw Accounts Payables tumbled 36.64% in 2021 before it surged 65.11% in 2022.
  • A 5-year view of Accounts Payables shows it stood at $61.8 million in 2021, then soared by 65.11% to $102.1 million in 2022, then dropped by 9.57% to $92.3 million in 2023, then decreased by 10.64% to $82.5 million in 2024, then rose by 16.03% to $95.7 million in 2025.
  • Per Business Quant, the three most recent readings for IART's Accounts Payables are $95.7 million (Q4 2025), $92.3 million (Q3 2025), and $92.8 million (Q2 2025).